Metabolic and endocrine effects of valproic acid chronic treatment

Epilepsy Research

Volumn 107, Issue 1-2, 2013, Pages 1-8

  Belcastro, Vincenzo ^a   D'Egidio, Claudia ^b   Striano, Pasquale ^c   Verrotti, Alberto ^d  

^a SANT ANNA HOSPITAL   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Atherosclerosis; Epileptic syndromes; Metabolic syndrome; Valproic acid

Indexed keywords

ADIPONECTIN; CARBAMAZEPINE; GHRELIN; HOMOCYSTEINE; INSULIN; LAMOTRIGINE; LEPTIN; LEPTIN RECEPTOR; PHENYTOIN; TOPIRAMATE; URIC ACID; VALPROIC ACID;

ATHEROSCLEROSIS; BODY WEIGHT; CARDIOVASCULAR RISK; CYTOKINE RELEASE; DISEASE ASSOCIATION; DYSLIPIDEMIA; EPILEPSY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERHOMOCYSTEINEMIA; HYPERINSULINEMIA; HYPERLEPTINEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERURICEMIA; INSULIN RESISTANCE; LONG TERM CARE; METABOLIC SYNDROME X; MORBIDITY; NONHUMAN; OXIDATIVE STRESS; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; WEIGHT GAIN;

ATHEROSCLEROSIS; EPILEPTIC SYNDROMES; METABOLIC SYNDROME; VALPROIC ACID;

ANTICONVULSANTS; EPILEPSY; HUMANS; HYPERINSULINISM; INSULIN RESISTANCE; LEPTIN; METABOLIC SYNDROME X; VALPROIC ACID; WEIGHT GAIN;

EID: 84886949545     PISSN: 09201211     EISSN: 18726844     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2013.08.016     Document Type: Review

References (102)

1. Abaci A., Saygi M., Yis U., Demir K., Dirik E., Bober E. Metabolic alterations during valproic acid treatment: a prospective study. Pediatr. Neurol. 2009, 41:435-439.
2. Alberti K.G., Zimmet P., Shaw J. Metabolic syndrome - a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet. Med. 2006, 23:469-480.
3. Angulo P. Nonalcoholic fatty liver disease. N. Engl. J. Med. 2002, 346:1221-1231.
4. Aldenkamp A., Vigevano F., Arzimanoglou A., Covanis A. Role of valproate across the ages. Treatment of epilepsy in children. Acta Neurol. Scand. 2006, 184:1-13.
5. Annegers J.F., Hauser W.A., Shirts S.B. Heart disease mortality and morbidity in patients with epilepsy. Epilepsia 1984, 25:699-704.
6. Arner P. Differences in lipolysis between human subcutaneous and omental adipose tissue. Ann. Med. 1995, 27:435-438.
7. Attilakos A., Papakonstantinou E., Schulpis K., Voudris K., Katsarou E., Mastroyianni, et al. Early effect of sodium valproate and carbamazepine monotherapy on homocysteine metabolism in children with epilepsy. Epilepsy Res. 2006, 71:229-232.
8. Aydin K., Serdaroglu A., Okuyaz C., Bideci A., Gucuyener K. Serum insulin, leptin, and neuropeptide y levels in epileptic children treated with valproate. J. Child Neurol. 2005, 20:848-851.
9. Belcastro V., Gorgone G., Italiano D., Oteri G., Caccamo D., Pisani L.R., et al. Antiepileptic drugs and MTHFR polymorphisms influence hyper-homocysteinemia recurrence in epileptic patients. Epilepsia 2007, 48:1990-1994.
10. Belcastro V., Striano P., Gorgone G., Costa C., Ciampa C., Caccamo D., et al. Hyperhomocysteinemia in epileptic patients on new antiepileptic drugs. Epilepsia 2010, 51:274-279.
11. Belcastro V., Striano P. Antiepileptic drugs, hyperhomocysteinemia and B-vitamins supplementation in patients with epilepsy. Epilepsy Res. 2012, 102:1-7.
12. Berenson G.S., Srinivasan S.R., Bao W., Newman W.P., Tracy R.E., Wattigney W.A. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med. 1998, 338:1650-1656.
13. Biton V., Levisohn P., Hoyler S., Vuong A., Hammer A.E. Lamotrigine versus valproate monotherapy-associated weight change in adolescents with epilepsy: results from a post hoc analysis of a randomized, double-blind clinical trial. J. Child Neurol. 2003, 18:133-139.
14. Breum L., Astrup A., Gram L., Andersen T., Stokholm K.H., Christensen N.J., et al. Metabolic changes during treatment with valproate in humans: implication for untoward weight gain. Metab. Clin. Exp. 1992, 41:666-670.
15. Brodie M.J., Mintzer S., Pack A.M., Gidal B.E., Vecht C.J., Schmidt D. Enzyme induction with antiepileptic drugs: cause for concern?. Epilepsia 2013, 54:11-27.
16. Brown R., Imran S.A., Ur E., Wilkinson M. Valproic acid and CEBPalpha-mediated regulation of adipokine gene expression in hypothalamic neurons and 3T3-L1 adipocytes. Neuroendocrinology 2008, 88:25-34.
17. Burton B.S. On the propyl derivatives and decomposition products of ethylacetoacetate. Am. Chem. J. 1882, 3:385-395.
18. Chuang Y.C., Chuang H.Y., Lin T.K., Chang C.C., Lu C.H., Chang W.N., et al. Effects of long-term antiepileptic drug monotherapy on vascular risk factors and atherosclerosis. Epilepsia 2012, 53:120-128.
19. de Almeida K.M., Moreira C.L., Lafer B. Metabolic syndrome and bipolar disorder: what should psychiatrists know?. CNS Neurosci. Ther. 2012, 18:160-166.
20. de Vries L., Karasik A., Landau Z., Phillip M., Kiviti S., Goldberg-Stern H. Endocrine effects of valproate in adolescent girls with epilepsy. Epilepsia 2007, 48:470-477.
21. Demir E., Aysun S. Weight gain associated with valproate in childhood. Pediatr. Neurol. 2000, 22:361-364.
22. Demircioglu S., Soylu A., Dirik E. Carbamazepine and valproic acid: effects on the serum lipids and liver functions in children. Pediatr. Neurol. 2000, 23:142-146.
23. Eirìs J.M., Lojo S., Del Rìo M.C., Novo I., Bravo M., Pavon P., et al. Effects of long-term treatment with antiepileptic drugs on serum lipid levels in children with epilepsy. Neurology 1995, 45:1155-1157.
24. Elliott J.O., Jacobson M.P., Haneef Z. Cardiovascular risk factors and homocysteine in epilepsy. Epilepsy Res. 2007, 76:113-123.
25. El-Khayat H.A., El-Basset F.Z., Tomoum H.Y., Tohamy S.M., Zaky A.A., Mohamed M.S., et al. Physical growth and endocrinal disorders during pubertal maturation in girls with epilepsy. Epilepsia 2004, 45:1106-1115.
26. El-Khatib F., Rauchenzauner M., Lechleitner M., Hoppichler F., Naser A., Waldmann M., et al. Valproate, weight gain and carbohydrate craving: a gender study. Seizure 2007, 16:226-232.
27. Erdemir A., Cullu N., Yis U., Demircioǧlu F., Kir M., Cakmakçi H., et al. Evaluation of serum lipids and carotid artery intima media thickness in epileptic children treated with valproic acid. Brain Dev. 2009, 31:713-716.
28. Evans J.L., Goldfine I.D., Maddux B.A., Grodsky G.M. Are oxidative stress-activated signaling pathways mediators of insulin resistance and beta-cell dysfunction?. Diabetes 2003, 52:1-8.
29. Fang J., Chen S., Tong N., Chen L., An D., Mu J., et al. Metabolic syndrome among Chinese obese patients with epilepsy on sodium valproate. Seizure 2012, 21:578-582.
30. Fu J.F., Liang L., Zou C.C., Hong F., Wang C.L., Wang X.M., et al. Prevalence of the metabolic syndrome in Zhejiang Chinese obese children and adolescents and the effect of metformin combined with lifestyle intervention. Int. J. Obes. 2007, 31:15-22.
31. Geda G., Caksen H., Icagasioglu D. Serum lipids, vitamin B12 and folic acid levels in children receiving long-term valproate therapy. Acta Neurol. Belg. 2002, 102:122-126.
32. Greco R., Latini G., Chiarelli F., Iannetti P., Verrotti A. Leptin, ghrelin, and adiponectin in epileptic patients treated with valproic acid. Neurology 2005, 65:1808-1809.
33. Grosso S., Mostardini R., Piccini B., Balestri P. Body mass index and serum lipid changes during treatment with valproic acid in children with epilepsy. Ann. Pharmacother. 2009, 43:45-50.
34. Gungor S., Yücel G., Akinci A., Tabel Y., Ozerol I.H., Yologlu S. The role of ghrelin in weight gain and growth in epileptic children using valproate. J. Child Neurol. 2007, 22:1384-1388.
35. Hamed S.A., Nabeshima T. The high atherosclerotic risk among epileptics: the atheroprotective role of multivitamins. J. Pharmacol. Sci. 2005, 98:340-353.
36. Hamed S.A., Hamed E.A., Hamdy R., Nabeshima T. Vascular risk factors and oxidative stress as independent predictors of asymptomatic atherosclerosis in adult patients with epilepsy. Epilepsy Res. 2007, 74:183-192.
37. Hamed S.A., Fida N.M., Hamed E.A. States of serum leptin and insulin in children with epilepsy: risk predictors of weight gain. Eur. J. Paediatr. Neurol. 2009, 13:261-268.
38. Hassan A., Hunt B.J., O'Sullivan M., Bell R., D'Souza R., Jeffery S., et al. Homocysteine is a risk factor for cerebral small vessel disease, acting via endothelial dysfunction. Brain 2004, 127:212-219.
39. Gaitatzis A., Carroll K., Majeed A.W., Sander J. The epidemiology of the comorbidity of epilepsy in the general population. Epilepsia 2004, 45:1613-1622.
40. Isojärvi J.I., Laatikainen T.J., Knip M., Pakarinen A.J., Juntunen K.T., Myllylä V.V. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann. Neurol. 1996, 39:579-584.
41. Isomaa B., Almgren P., Tuomi T., Forsen B., Lahti K., Nissen M., et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001, 24:683-689.
42. Johannessen Landmark C. Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy. CNS Drugs 2008, 22:27-47.
43. Kanemura H., Sano F., Maeda Y., Sugita K., Aihara M. Valproate sodium enhances body weight gain in patients with childhood epilepsy: a pathogenic mechanisms and open-label clinical trial of behavior therapy. Seizure 2012, 21:496-500.
44. Karabiber H., Sonmezgoz E., Ozerol E., Yakinci C., Otlu B., Yologlu S. Effects of valproate and carbamazepine on serum levels of homocysteine, vitamin B12, and folic acid. Brain Dev. 2003, 25:113-115.
45. Kaste M., Muuronen A., Nikkilä E.A., Neuvonen P.J. Increase of low serum concentrations of high-density lipoprotein (HDL) cholesterol in TIA-patients treated with phenytoin. Stroke 1983, 14:525-530.
46. Kullo I.J., Ballantyne C.M. Conditional risk factors for atherosclerosis. Mayo Clin. Proc. 2005, 80:219-230.
47. Lakhanpal D., Kau G. Valproic acid alters GnRH-GABA interactions in cycling female rats. Cell. Mol. Neurobiol. 2007, 27:1069-1083.
48. Lakka H.M., Laaksonen D.E., Lakka T.A., Niskanen L.K., Kumpusalo E., Tuomilehto J., et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002, 288:2709-2716.
49. Lewis G.F., Steiner G. Acute effects of insulin in the control of VLDL production in humans. Implications for the insulin-resistant state. Diabetes Care 1996, 19:390-393.
50. Lihn A.S., Pedersen S.B., Richelsen B. Adiponectin: action, regulation and association to insulin sensitivity. Obes. Rev. 2005, 6:13-21.
51. Lopinto-Khoury C., Mintzer S. Antiepileptic drugs and markers of vascular risk. Curr. Treat. Options Neurol. 2010, 12:300-308.
52. Luef G., Abraham I., Trinka E., Alge A., Windisch J., Daxenbichler G., et al. Hyperandrogenism, postprandial hyperinsulinism and the risk of PCOS in a cross-sectional study of women with epilepsy treated with valproate. Epilepsy Res. 2002, 2(48):91-102.
53. Luef G., Abraham I., Hoppichler F., Trinka E., Unterberger I., Bauer G., et al. Increase in postprandial serum insulin levels in epileptic patients with valproic acid therapy. Metab. Clin. Exp. 2002, 51:1274-1278.
54. Luef G., Waldmann M., Sturm W., Naser A., Trinka E., Unterberger I., et al. Valproate therapy and non-alcoholic fatty liver disease. Ann. Neurol. 2004, 55:729-732.
55. Luef G., Rauchenzauner M., Waldmann M., Sturm W., Sandhofer A., Seppi K., et al. Non-alcoholic fatty liver disease (NAFLD), insulin resistance and lipid profile in antiepileptic drug treatment. Epilepsy Res. 2009, 86:42-47.
56. Marchesini G., Brizi M., Bianchi G., Tomassetti S., Bugianesi E., Lenzi M., et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001, 50:1844-1850.
57. Mattson M.P., Shea T.B. Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders. Trends Neurosci. 2003, 26:137-146.
58. McGarry J.D. Dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 2002, 51:7-18.
59. Meunier H., Carraz G., Neunier Y., Eymard P., Aimard M. Pharmacodynamic properties of ndipropylacetic acid. Therapie 1963, 18:435-438.
60. Mikkonen K., Knip M., Pakarinen A.J., Lanning P., Isojärvi J., Vainionpää L.K. Growth and lipid metabolism in girls and young women with epilepsy during pubertal maturation. Epilepsia 2005, 46:1114-1120.
61. Mintzer S., Mattson R.T. Should enzyme-inducing antiepileptic drugs be considered first-line agents?. Epilepsia 2009, 50:42-50.
62. Mottillo S., Filion K.B., Genest J., Joseph L., Pilote L., Poirier P., et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J. Am. Coll. Cardiol. 2010, 56:1113-1132.
63. Münzberg H., Myers M.G. Molecular and anatomical determinants of central leptin resistance. Nat. Neurosci. 2005, 8:566-570.
64. Muuronen A., Kaste M., Nikkila E.A., Tolppanen E.M. Mortality from ischemic heart disease among the patients using anticonvulsant drugs. A case control study. BMJ 1985, 291:1481-1483.
65. Ness-Abramof R., Apovian C.M. Drug-induced weight gain. Drugs Today 2005, 41:547-555.
66. Nikolaos T., Stylianos G., Chryssoula N., Irini P., Christos M., Dimitrios T. The effect of long-term antiepileptic treatment on serum cholesterol (TC, HDL, LDL) and triglycerid elevels in adult epileptic patients on monotherapy. Med. Sci. Monit. 2004, 10:50-52.
67. Novak G.P., Maytal J., Alshansky A., Eviatar L., Sy-Kho R., Siddique Q. Risk of excessive weight gain in epileptic children treated with valproate. J. Child Neurol. 1999, 14:490-495.
68. Olesen J.B., Hansen P.R., Abildstrøm S.Z., Andersson C., Weeke P., Schmiegelow M., et al. Valproate attenuates the risk of myocardial infarction in patients with epilepsy: a nationwide cohort study. Pharmacoepidemiol. Drug. Saf. 2011, 20:146-153.
69. Patsch J.R., Miesenbock G., Hopferwieser T., Muhlberger V., Knapp E., Dunn J.K., et al. Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state. Arterioscler. Thromb. 1992, 12:136-141.
70. Polak J.F., Pencina M.J., Pencina K.M., O'Donnell C.J., Wolf P.A., D'Agostino R.B. Carotid-wall intima-media thickness and cardiovascular events. N. Engl. J. Med. 2011, 365:213-221.
71. Privitera M.D., Brodie M.J., Mattson R.H., Chadwick D.W., Neto W., Wang S., et al. Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol. Scand. 2003, 107:165-175.
72. Prabhakar S., Sahota P., Kharbanda P.S., Siali R., Jain V., Lal V. Sodium valproate, hyperandrogenism and altered ovarian function in Indian women with epilepsy: a prospective study. Epilepsia 2007, 48:1371-1377.
73. Prodam F., Ricotti R., Genoni G., Parlamento S., Petri A., Balossini C., et al. Comparison of two classifications of metabolic syndrome in the pediatric population and the impact of cholesterol. J. Endocrinol. Invest. 2012.
74. Pylvänen V., Knip M., Pakarinen A., Kotila M., Turkka J., Isojärvi J.I. Serum insulin and leptin levels in valproate-associated obesity. Epilepsia 2002, 43:514-517.
75. Pylvänen V., Knip M., Pakarinen A.J., Turkka J., Kotila M., Rättyä J., et al. Fasting serum insulin and lipid levels in men with epilepsy. Neurology 2003, 60:571-574.
76. Pylvänen V., Pakarinen A., Knip M., Isojärvi J. Insulin-related metabolic changes during treatment with valproate in patients with epilepsy. Epilepsy Behav. 2006, 8:643-648.
77. Qiao L., Schaack J., Shao J. Suppression of adiponectin gene expression by histone deacetylase inhibitor valproic acid. Endocrinology 2006, 147:865-874.
78. Rättyä J., Vainionpää L., Knip M., Lanning P., Isojärvi J.I. The effects of valproate, carbamazepine, and oxcarbazepine on growth and sexual maturation in girls with epilepsy. Pediatrics 1999, 103:588-593.
79. Rauchenzauner M., Laimer M., Luef G., Kaser S., Engl J., Tatarczyk T., et al. Adiponectin receptor R1 is upregulated by valproic acid but not by topiramate in human hepatoma cell line, HepG2. Seizure 2008, 17:723-726.
80. Rauchenzauner M., Haberlandt E., Scholl-Bürgi S., Karall D., Schoenherr E., Tatarczyk T., et al. Effect of valproic acid treatment on body composition, leptin and the soluble leptin receptor in epileptic children. Epilepsy Res. 2008, 80:142-149.
81. Rauchenzauner M., Haberlandt E., Scholl-Bürgi S., Ernst B., Hoppichler F., Karall D., et al. Adiponectin and visfatin concentrations in children treated with valproic acid. Epilepsia 2008, 49:353-357.
82. Rauchenzaunera M., Laimerb M., Wiedmannc M., Tschonerb A., Salzmannb K., Sturmb W., et al. The novel insulin resistance parameters RBP4 and GLP-1 in patients treated with valproic acid: Just a sidestep?. Epilepsy Res. 2012, 10.1016/j.eplepsyres.2012.10.004.
83. Sharpe C., Wolfson T., Trauner D.A. Weight gain in children treated with valproate. J. Child Neurol. 2009, 24:338-341.
84. Sonmez F.M., Demir E., Orem A., Yildirmis S., Orhan F., Aslan A., et al. Effect of antiepileptic drugs on plasma lipids, lipoprotein (a), and liver enzymes. J. Child Neurol. 2006, 21:70-74.
85. Sthephen L.J., Kwan P., Shapiro D., Dominiczak M., Brodie M.J. Hormone profiles in young adults with epilepsy treated with sodium valproate or lamotrigine monotherapy. Epilepsia 2001, 42:1002-1006.
86. Stiemer B. Morphological evaluation of steatosis in mono-layer cultures (MDCK cells) after treatment with gentamicin and valproic acid. Histol. Histopathol. 1989, 4:421-428.
87. Stocker R., Keaney J.F. Role of oxidative modifications in atherosclerosis. Physiol. Rev. 2004, 84:1381-1478.
88. Strong J.P., Zieske A.W., Malcom G.T. Lipoproteins and atherosclerosis in children: an early marriage?. Nutr. Metab. Cardiovasc. Dis. 2001, 11:16-22.
89. Striano P., Belcastro V. Treatment of myoclonic seizures. Expert Rev. Neurother. 2012, 12:1411-1418.
90. Striano P., Belcastro V. Treating myoclonic epilepsy in children: state of the art. Expert Opin. Pharmacother. 2013, 14:1355-1361.
91. Tan T.Y., Lu C.H., Chuang H.Y., Lin T.K., Liou C.W., Chang W.N., et al. Long-term antiepileptic drug therapy contributes to the acceleration of atherosclerosis. Epilepsia 2009, 50:1579-1586.
92. Temple M.E., Luzier A.B., Kazierad D.J. Homocysteine as a risk factor for atherosclerosis. Ann. Pharmacother. 2000, 34:57-65.
93. Tomoum H.Y., Awadallah M.M., Fouad D.A., Ali A.H. Lipid profile, apolipoproteins A and B in children with epilepsy. J. Child Neurol. 2008, 23:1275-1281.
94. van der Lely A.J., Tschöp M., Heiman M.L., Ghigo E. Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr. Rev. 2004, 25:426-457.
95. Verrotti A., Basciani F., Morresi S., de Martino M., Morgese G., Chiarelli F. Serum leptin changes in epileptic patients who gain weight after therapy with valproic acid. Neurology 1999, 53:230-232.
96. Verrotti A., Pascarella R., Trotta D., Giuva T., Morgese G., Chiarelli F. Hyperhomocysteinemia in children treated with sodium valproate and carbamazepine. Epilepsy Res. 2000, 41:253-257.
97. Verrotti A., Basciani F., De Simone M., Trotta D., Morgese G., Chiarelli F. Insulin resistance in epileptic girls who gain weight after therapy with valproic acid. J. Child Neurol. 2002, 17:265-268.
98. Verrotti A., Greco R., Latini G., De Simone M., Chiarelli F. Obesity and plasma concentrations of alpha-tocopherol and beta-carotene in epileptic girls treated with valproate. Neuroendocrinology 2004, 79:157-162.
99. Verrotti A., Manco R., Agostinelli S., Coppola G., Chiarelli F. The metabolic syndrome in overweight epileptic patients treated with valproic acid. Epilepsia 2010, 51:268-273.
100. Voudris K.A., Attilakos A., Katsarou E., et al. Early and persistent increase in serum lipoprotein (a) concentrations in epileptic children treated with carbamazepine and sodium valproate monother-apy. Epilepsy Res. 2006, 70:211-217.
101. Wang B., Liu Y., He P., Dong B., Ou Yang L., Ma Y., et al. Prevalence of metabolic syndrome in an elderly Chinese population: a community-based cross-sectional study. J. Am. Geriatr. Soc. 2010, 58:2027-2028.
102. Yiş U., Doǧan M. Effects of oxcarbazepine treatment on serum lipids and carotid intima media thickness in children. Brain Dev. 2012, 34:185-188.